Try our beta test site
51 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND brentuximab vedotin [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 25
Study Start: August 2015
2 Recruiting A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 20
Study Start: September 2014
3 Recruiting Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 20
Study Start: May 2015
4 Recruiting Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Study Type: Interventional
Phase: Early Phase 1
Number Enrolled: 25
Study Start: April 2014
5 Not yet recruiting To Assess the Efficacy of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 33
Study Start: November 2014
6 Recruiting Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Study Type: Interventional
Phases: Phase 1 / Phase 2
Number Enrolled: 10
Study Start: May 2015
7 Recruiting Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Study Type: Interventional
Phase: Phase 1
Number Enrolled: 48
Study Start: September 18, 2014
8 Recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Study Type: Interventional
Phases: Phase 1 / Phase 2
Number Enrolled: 71
Study Start: July 2012
9 Recruiting A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Study Type: Interventional
Phases: Phase 1 / Phase 2
Number Enrolled: 60
Study Start: October 2015
10 Recruiting Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Study Type: Interventional
Phases: Phase 1 / Phase 2
Number Enrolled: 44
Study Start: April 2015
11 Recruiting Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Study Type: Interventional
Phase: Phase 3
Number Enrolled: 300
Study Start: May 2016
12 Recruiting Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 34
Study Start: July 2015
13 Recruiting Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 30
Study Start: November 2016
14 Not yet recruiting Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Study Type: Interventional
Phase: Phase 1
Number Enrolled: 24
Study Start: September 2016
15 Not yet recruiting A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Study Type: Interventional
Phase: Phase 1
Number Enrolled: 27
Study Start: April 2017
16 Recruiting Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Study Type: Observational
Phase:
Number Enrolled: 140
Study Start: April 2014
17 Recruiting Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 70
Study Start: September 2015
18 Not yet recruiting Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Study Type: Interventional
Phases: Phase 1 / Phase 2
Number Enrolled: 30
Study Start: December 2016
19 Recruiting Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 39
Study Start: June 2016
20 Recruiting Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
Study Type: Interventional
Phase: Phase 2
Number Enrolled: 40
Study Start: April 2015

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.